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Abstract We have shown previously that ICRF-193, a catalytic 
inhibitor of DNA topoisomerase II (topo II), delays cell cycle 
progression in HeLa S3 cells. We report here that the delay of 
the transition in M phase is observed when HeLa S3 cells were 
treated with ICRF-193 during metaphase, but not thereafter. 
ICRF-193 also delayed the degradation of cyclin B in the 
transition from M to Gl phase, while in Chinese hamster ovary 
(CHO) cells the drug did not delay the progression in M phase. 
Since HeLa S3 and CHO cells are 'stringent' and 'relaxed' in 
mitotic control, respectively, it is suggested that under topo II 
inhibition, the M phase checkpoint operates through an inability 
for chromosome segregation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cells have a system termed 'checkpoint control' by which 
an event does not begin until previous events have been com-
pleted. The function of cell cycle arrest is well understood, 
based on studies of rod 9 mutants in budding yeast [1], where-
by UV- or X-irradiated wild type cells are arrested in G2 
phase and do not restart cell cycle progression until after 
DNA damage has been repaired. In contrast, irradiated rad 
9 mutants do not remain in G2, but enter mitosis with unre-
paired damage, and suffer mortality. In mammalian cells, loss 
of p53 function, a tumor suppressor protein often associated 
with an increased frequency of gene amplification and aneu-
ploidy, results in defects in the Gl and G2 checkpoints [2,3]. 
Cells from patients with ataxia telangiectasia, a human reces-
sive disorder, exhibit increased sensitivity to ionizing radiation 
but are unresponsive to the normally associated inhibition of 
DNA synthesis and do not demonstrate G2 arrest [4]. Inhib-
itors of microtubule formation block cell cycle progression at 
prometaphase, and improper attachment of kinetochore spin-
dles to chromosomes delays the progression from metaphase 
to anaphase [5]. Defects in the driving force of the mitotic 
spindle also delay the transition to telophase [6]. 
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Topo I and II are enzymes which control DNA topology by 
introducing transient single and double strands breaks, respec-
tively, into DNA. In DNA replication and transcription, these 
enzymes resolve the torsional constraints which accumulate 
ahead of macromolecular synthesis [7]. Topo II functions as 
a decatenase in mitotic chromosome condensation, deconden-
sation and segregation [8,9]. In mammalian cells, it has also 
been shown to play an important role in chromosome con-
densation, as determined using Xenopus oocyte extracts 
[10,11]. 
Our recent work revealed that ICRF-193, a non-cleavable 
complex forming type of topo II inhibitor [12-14], allows cell 
cycle progression without chromosome segregation, leading to 
the accumulation of multiploid cells [13,15]. We further found 
that ICRF-193 delays transition from S to M phase and from 
M to Gl phase in HeLa S3 cells [15]. In the present study, we 
examined the phase of mitosis in which the checkpoint control 
functions with topo II inhibition. 
2. Materials and methods 
2.1. Drugs 
ICRF-193 and CPT-11 were kindly provided by Zenyaku Kogyo 
Co., Ltd. (Tokyo) and Yakult Honsha Co., Ltd. (Tokyo), respec-
tively. TN-16 was purchased from Wako Pure Chemical Industries 
Ltd. (Osaka). 
2.2. Cell culture 
HeLa S3 and a Chinese hamster ovary (CHO) cell line, AA8, were 
seeded in 60 mm dishes, and grown in Dulbecco's modified Eagle's 
(DME) medium containing 10% calf serum under a humidified atmos-
phere of 5% CO2 in air. 
2.3. M phase synchronization 
Cells were seeded at 1 or 2X106 cells/140 mm dish. The next day, 
TN-16 was added (final concentration 0.3 uM), after which HeLa S3 
cells were cultured for 5 h, and CHO cells for 3 h [15]. Round and 
floating mitotic cells were then collected and washed with serum free 
DME. 
2.4. Mitotic figures 
To examine the mitotic index, cells were suspended in 75 mM KC1, 
and left to stand for 20 min at 0°C. An equal volume of methanol-
acetic acid (3:1) (MeA) was then added to the suspension, with mild 
agitation before centrifugation. After washing with MeA solution, the 
cells were resuspended in MeA solution and dispensed onto glass 
slides. After drying, the samples were stained with Giemsa solution. 
Mitotic cells were counted under a microscope. To determine the 
population of cells in M phase, staining of DNA with propidium 
iodide and of microtubules with anti-tubulin a antibody was also 
performed. 
2.5. Immunoblotting 
HeLa S3 cells were pelleted at 3000 rpm for 5 min at 4°C, and lysed 
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Fig. 1. Inhibition of the exit from M phase in HeLa S3 cells by 
ICRF-193 but not CPT-11, in a dose dependent manner. Mitotic 
cells were collected in the presence of TN-16, and after its removal 
were incubated with various concentrations of ICRF-193 (o) or 
CPT-11 (•). Percentages of mitotic cells were counted 2 h after re-
lease from metaphase. The synchrony of mitotic cells was 80% at 
the beginning. 
of increasing concentrations of ICRF-193 on the progression 
from M to Gl phase in HeLa S3 cells, expressed as the per-
centage of mitotic cells remaining 2 h after release from TN-
16, a mitotic inhibitor. 10 uM or higher concentrations of 
ICRF-193 significantly inhibited the transition. Since topo I 
does not play a role in chromosome dynamics such as con-
densation or segregation, the effect of CPT-11, a topo I in-
hibitor, was examined as a control. The drug did not inhibit 
the M phase transition. At 30 uM, ICRF-193 delayed the exit 
from M phase for over 5 h (Fig. 2A). Downes et al. [17] have 
shown that caffeine can overcome ICRF-193 effects. We con-
firmed their data, but found that caffeine does not prevent the 
ICRF-193-induced delay in progression through the M phase 
(Fig. 2A). As shown in Fig. 2B, reduction in cyclin B levels 
was also delayed by ICRF-193. To determine whether ICRF-
193 treatment exerts the same effects on HeLa S3 cells in 
anaphase or telophase, they were exposed to 30 |j.M ICRF-
193 at various times after removal of TN-16, and the percent-
age of mitotic cells was examined (Fig. 3). The addition of 
ICRF-193 to mitotic cells after 0 or 15 min resulted in com-
plete inhibition of progression, with most cells in M phase 
after 2 h. With exposure after 30 min or later, cell cycle pro-
gression was only slightly delayed and the cells did exit from 
M phase. No inhibition was observed when cells were exposed 
to the drug after 60 min. Morphological assessment revealed 
no cells in anaphase at 15 min. At 30 min, however, about 
12% of cells were in anaphase, and at 45 min, cells in ana-
on ice for 1 h by resuspension in cold lysis buffer (50 mM Tris-HCl 
buffer, 350 mM NaCl, 0.1% (v/v) Nonidet P-40, 5 mM Na2EDTA, 50 
mM NaF, pH 7.4) containing protease inhibitors (2 mM phenyl-
methylsulfonyl fluoride and 20 ug/ml each of antipain, aprotinin, chy-
mostatin, leupeptin and pepstatin A) and then centrifuged at 15 000 
rpm for 15 min at 4°C. The supernatants were used for immunoblot-
ting after addition of 3 X SDS-PAGE loading buffer and boiling. The 
samples were subjected to electrophoresis on 7.5% polyacrylamide gels 
and electroblotted onto nitrocellulose membranes, which were then 
blocked with 5% skim milk and incubated with anti-mouse cyclin 
Bl antibody (Oncogene Science). After washing with TBST (Tris-buf-
fered saline-Tween), the membranes were treated with HRP-conju-
gated goat anti-mouse IgG. The blots were visualized by enhanced 
chemiluminescence (ECL), using the ECL Western blot detection sys-
tem (Amersham). 
3. Results 
We previously clarified ICRF-193 to be a non-cleavable 
complex forming type of topo II inhibitor [12-14]. The drug 
inhibits the release of topo II from DNA after one round of 
the catalytic cycle through inhibition of the enzyme's ATPase 
activity, and stabilizes it in a protein closed clamp which 
cannot be dissociated with 1 M NaCl [14]. Since it is difficult 
to test directly whether or not ICRF-193 inhibits topo II 
activity in situ within the cells, we examined the amount of 
topo II in this closed protein clamp. The intracellular topo II 
formed a salt stable complex in the presence of ICRF-193. 
In previous work, we showed that cell cycle progression 
from S to M and M to Gl phases is delayed by ICRF-193 
in HeLa S3 but not in CHO cells [15]. To further examine this 
delay in progression, we also tested the effect of ICRF-193 on 
the degradation of cyclin B in M to Gl transition, which 
normally occurs concomitant with a decrease of cdc 2 kinase 
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Fig. 2. ICRF-193-induced delay of the cell cycle progression (A) 
and degradation of cyclin B (B) in M phase. A: After removal of 
TN-16, mitotic HeLa S3 cells were exposed to no drug (•), 30 uM 
ICRF-193 (O), 2 mM caffeine and 30 uM ICRF-193 ( A ) or 2 mM 
caffeine ( A ) . Percentages of mitotic cells were determined by count-
ing cells having no nuclear envelope. The amount of cyclin B (B) 
was examined by immunoblot analysis using anti-cyclin B antibody 
at the indicated times after release from TN-16. 
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Fig. 3. ICRF-193 delays the cell cycle transition in metaphase, but not in anaphase. A: HeLa S3 cells were exposed to no drug (o) or to 30 
uM ICRF-193 at 0 (•), 15 (■), 30 ( A ) , 45 ( ♦ ) and 60 (▼) min after removal of TN-16 and incubated further. Percentages of mitotic cells 
were examined at the times indicated. B: Cells were fixed at 0, 15, 30, 45 or 60 min after removal of TN-16 and prepared for indirect immuno-
fluorescence with anti-tubulin a antibody (light color) and propidium iodide (gray color). 
phase and telophase accounted for 71% of the population 
(Fig. 3B). These results indicate that the inhibition of topo 
II by ICRF-193 affects the transition in metaphase, but not in 
anaphase or telophase. 
Differing from HeLa S3 cells, CHO cells were not delayed 
by ICRF-193 in the progression from M to Gl phase (data 
not shown). 
4. Discussion 
In the present study we confirmed our previous findings 
that the inhibition of topo II by ICRF-193 delays transition 
of cells from the M to the Gl phase, in contrast with the 
results of Downes et al. [16]. Furthermore, we demonstrated 
that the inhibitor-induced delay occurs when cells were ex-
posed to ICRF-193 during metaphase, but not thereafter. 
Since ICRF-193 inhibits chromosome segregation, this indi-
cates that an inability for chromosome segregation causes the 
delay in progression. Downes et al. [16] earlier showed caf-
feine to abrogate the ICRF-induced delay in the transition 
from the S to the M phase. Using HeLa S3 cells, we confirmed 
their observation (data not shown), but further found that 
caffeine did not reverse the delay of transition during M 
phase. Caffeine has been reported to potentiate UV-, X-ray-
or drug-induced lethal damage and inhibit post-replicational 
repair by abrogating G2 arrest and leading to abortive mitosis 
[18]. Although caffeine is an inhibitor of phosphodiesterase, it 
is not known why the drug overcomes G2 arrest and poten-
tiates cell killing induced by DNA damaging agents [19]. 
As reported previously [15], neither transition from the S to 
M phase nor progression through M phase was affected by 
ICRF-193 in CHO cells. HeLa S3 and CHO cells have also 
been shown to have different responses to inhibitors of the 
mitotic spindle assembly, such as colcemid and nocodazole, 
and DNA synthesis inhibitors such as hydroxyurea and aphi-
dicolin [20,21]; only HeLa S3 cells are blocked at M phase by 
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the presence of colcemid. In contrast, C H O cells continue cell 
cycle progression without cell division. The difference is that 
protein synthesis is down-regulated under inhibition of D N A 
synthesis in HeLa S3 cells, so that they become arrested in S 
phase, while protein synthesis continues in C H O cells and 
unbalanced growth ensues. Our present observations offer fur-
ther evidence that the checkpoint control functions under in-
hibition of topo II activity in HeLa S3, but not in C H O cells. 
In the M phase, inhibitors of microtubule assembly block 
cell cycle progression at prometaphase by improper attach-
ment of kinetochore spindles to chromosomes, or reduced 
microtubule dynamics [22-25]. Such improper at tachment of 
kinetochores impairs the force driving the mitotic spindle and 
delays transition from metaphase to anaphase and telophase 
[6,21]. The fact that ICRF-193 delayed the progression from 
metaphase to anaphase, but not from anaphase to G l phase, 
suggests that the delay is related to an inability for chromo-
some segregation through inactivation of topo II activity. 
Although it remains to be clarified how topo II is involved 
in chromosome segregation, based on findings of yeast genetic 
studies, it is very likely that the enzyme removes catenated 
dimer D N A s remaining in the M phase so that sister chroma-
tids can segregate [26]. Since both inhibitors of microtubule 
assembly and topo II cause chromosome disaggregation, this 
might be a signal for the M phase checkpoint. 
Mclntosh [22] proposed that cells possess a signal inhibiting 
anaphase onset, which is turned off when proper at tachment 
of microtubules to kinetochores takes place at the metaphase 
plate. Gorbsky [27] described one candidate for the inhibitory 
signal: a phosphoepitope, associated with kinetochores, whose 
expression is reduced when chromosomes are aligned with the 
metaphase plate. Such an inhibitory signal would not be ex-
pected to disappear when cells in metaphase progress into 
anaphase in the presence of ICRF-193 because microtubules 
do not connect properly to the D N A of kinetochores resulting 
in a disordered D N A structure containing catenated dimers. 
To test this possibility, detailed analysis of the connections 
between kinetochores and microtubules in mitotic cells ex-
posed to ICRF-193 is necessary. 
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